Low-molecular-weight peptidyl aldehyde inhibitors of HIV protease that reach in vivo plasma concentrations after oral administration substantiailly in excess of the antiviral IC90 are described. We also report efforts to improve the potency and stability of these compounds that culminated in a series of peptidyl trifluoromethyl ketones with increased potency but decreased bioavailability.
References
1.
AgyM.B.FrumkinL.R.CoreyL.CoombsR.W.WolinskyS.M.KoehlerJ.MortonW.R., and KatzeM.G. (1992) Infection of Macaca nemestrina by Human Immunodeficiency Virus Type-1. Science257: 103–106.
2.
ChengY.-S.E.YinF.H.FoundlingS.BlomstromD., and KettnerC.A. (1990a) Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci USA87: 9660–9664.
3.
ChengY.-S.E.McGowanM.H.KettnerC.A.SchlossJ.V.Erickson-ViitanenS., and YinF.H. (1990b) High level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene87: 238–243.
4.
DebouckC. (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retrovirus8: 153–164.
5.
DessB., and MartinJ.C. (1983) Readily accessible 12–1–5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J Org Chem48: 4155–4156.
6.
FreudenbergerJ.H.KonradiA.W., and PedersenS.F. (1989) Intermolecular pinacol cross coupling of electronically similar aldehydes. An efficient and stereoselective synthesis of 1,2-diols employing a practical vanadium(***ll) reagent. J Am Chem Soc111: 8014–8016.
7.
GreenleeW.K., and SiegelP.K.S. (1991) Chapter 7: Angiotensin/Renin modulators: renin inhibitors. Ann Rep and Med Chem26: 64–66.
8.
HoreckerB.L.Erickson-ViitanenS., and HannappelE. (1983) Thymosin B4 like peptides. Methods Enzymol116: 265–267.
9.
HuffJ. (1991) HIV Protease: A novel chemotherapeutic target for AIDS. J Med Chem34: 2305–2314.
10.
ImperialiB., and AbelesR.H. (1986) Inhibition of serine protease by peptidyl fluoromethyl ketones. Biochemistry25: 3760–3767.
11.
JadhavP.K., and WoernerF. (1992) Synthesis of C2-Symmetric HIV-1 Protease Inhibitors from D-Mannitol. Biorganic & Medicinal Chemistry Letters2: 353–354.
12.
JadhavP.McGeeL.ShenviA., and HodgeC.N. (1991) New 1,4-Di:amino-2,3-di:hydroxybutane Derivatives. World Patent, W***O 9118-866-A.
13.
KempfD.J.NorbeckD.W.CodacoviL.WangX.C.KohlbrennerW.E.WideburgN.E.PaulD.A.KniggeM.F.VasavanondaS.Craig-KennardA.AaldivarA.RosenbrookW.JrClementJ.J.PlattnerJ.J.EricksonJ. (1990) Structure based C2 symmetric inhibitors of HIV proteinase. J Med Chem33: 2687–2689.
14.
KempfD.J.CodacoviL.WangX.C.KohlbrennerW.E.WideburgN.E.SalfivarA.VasavanondaS.MarchK.C.BryantP.ShamH.L.GreenB.E.BetebennerD.A.EricksonJ., and NorbreckD.W. (1993) Symmetry based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem36: 320–330.
15.
KohlN.E.EminiE.A.SchleifW.A.DavisL.J.HeimbachJ.C.DixonRAScolnickE.M., and SigalI.S. (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA85(13): 4686–4690.
16.
LaemmliU.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London)227: 680–685.
17.
LamP.Y.EyermannC.J.JadhavP.K.HodgeC.N.RuY.BachelerL.T.MeekJ.L.OttoM.J.RaynerM.M.WongY.N.ChangC-H.WeberP.C.JacksonD.A.SharpeT.R., and Erickson-ViitanenS. (1994) Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science263: 380–384.
18.
LustigE. (1961) J Phys Chem65: 491.
19.
McCuneJ.M. (1991) HIV-1: The Infective Process In Vivo. Cell64: 351–363.
20.
MosierD.E.GuliziaR.J.BairdS.M.WilsonD.B.SpectorD.H., and SpectorS.A. (1991) Human Immunodeficiency Virus Infection of Human-PBL-SCID Mice. Science251: 791–794.
21.
PatelD.V.Rielly-GauvinK.RyonoD.E.FreeC.A.SmithS.A., and PetrilloE.W. (1993) Activated ketone based inhibitors of human renin. J Med Chem36: 2431–2447.
22.
PeetN.P.BurkhartJ.P.AngelastroM.R.GirouxE.L.MehdiS.BeyP.KolbM.NeisesB., and SchirlinD. (1990) Synthesis of peptidyl fluoromethyl ketones and peptidyl α-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase and rat and human neutrophil cathepsin G. J Med Chem33: 394–407.
23.
PengC.HoB.K.ChangT.W., and ChangN.T. (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol63(6): 2550–2556.
24.
PhillipsD.D. (1958) Ann NY Acad Sci70: 817.
25.
RichD.H. (1986) Inhibitors of Aspartic Proteinases. In Proteinase Inhibitors.BarrettA.J., and SalvesanG. (eds). New York: Elsevier, pp. 179–217.
26.
RosenbergS.H.KleinenH.D.SteinH.H.MartinD.L.ChekalM.A.CohenJ.EganD.A.TricaricoK.A., and BakerW.R. (1991) Design of a well-absorbed renin inhibitor. J Med Chem34: 469–471.
27.
SarubbiE.SeneciP.AngelastroM.PeetN.DenaroM., and IslamK. (1993) Peptide aldehydes as inhibitors of HIV protease. FEBS Lett319: 253–256.
28.
ShamH.L.BetebennerD.A.WideburgN.E.SaldivarA.C.KohlbrennerW.E.VasavanondaS.KempfD.E.NorbeckD.W.ZaoC.ClementJ.J.EricksonJ.E., and PlattnerJ.J. (1991) Potent HIV-1 protease inhibitors with antiviral activities in vitro. Biochem Biophys Res Comm175: 914–919.
29.
SmallheerJ.M.OttoM.J.Amarli-LyC.A.EarlR.A.MyersM.J.PennevP.MontefioriD.C., and WuonolaM.A. (1993) Synthesis and anti-HIV activity of a series of 2-indolinones and related analogues. Antiviral Chem Chemother4: 27–39.
30.
StellaS.SaddlerG.SarubbiE.ColomboL.StefanelliS.DenaroM.SelvaE. (1991) Isolation of alpha-MAPI from fermentation broths during a screening program for HIV-1 protease inhibitors. J Antibiot44: 1019–1022.
31.
WlodawerA., and EricksonJ. (1993) Structure-Based Inhibitors of HIV Protease. Ann Rev Biochem62: 543–585.
